Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CARISSA Trial - Multicenter Randomized Phase II Trial Comparing Post-Operative Radiotherapy and Cisplatin Alone or in Combination With the EGFR Inhibitor ZD 1839 (Iressa) [gefitinib] in Upper Aerodigestive Tract Carcinomas

Next Previous
Trial Profile

CARISSA Trial - Multicenter Randomized Phase II Trial Comparing Post-Operative Radiotherapy and Cisplatin Alone or in Combination With the EGFR Inhibitor ZD 1839 (Iressa) [gefitinib] in Upper Aerodigestive Tract Carcinomas

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gefitinib (Primary) ; Cisplatin
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Acronyms CARISSA; GORTEC GETTEC CARISSA

    • Most Recent Events

    • 14 Nov 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 14 Nov 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 07 Jun 2010 Researchers in this trial are aiming to identify a subgroup of patients with head and neck cancer who are sensitive to gefitinib. According to an abstract presented at ASCO 2010, samples from 82 patients have been collected towards this end, to date.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top